Navigation Links
Treatment with PEGASYS(R)/COPEGUS(TM) Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron(R)/Ribavirin
Date:11/2/2007

- Response at 12 weeks is a powerful predictor of eventual treatment

success -

BOSTON, Nov. 2 /PRNewswire/ -- Roche today announced final results from the REPEAT study, which demonstrated that treatment with once-weekly PEGASYS(R) (peginterferon alfa-2a) and daily COPEGUS(TM) (ribavirin) for 72 weeks is a promising treatment option for patients whose infection did not respond to previous treatment with another pegylated interferon (Peg- Intron(R), peginterferon alfa-2b) and ribavirin. Further, the results showed that response at 12 weeks was a powerful predictor of the eventual outcome: the majority of patients with undetectable virus at 12 weeks went on to achieve a sustained virological response (SVR) after 72 weeks of treatment, while few patients with detectable virus at 12 weeks achieved SVR. These data were presented in an oral session at the 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), being held in Boston, Nov. 2-6.

"One of the greatest areas of need in hepatitis C today is to find solutions for patients who have not seen treatment success with an initial course of therapy. REPEAT is an important study which adds significantly to our knowledge about how to manage these patients, demonstrating that extending treatment with PEGASYS and COPEGUS is a promising option," said Donald Jensen, M.D., Professor of Medicine and Director of the Center for Liver Diseases at the University of Chicago Hospital in Chicago, and lead investigator in REPEAT. "A significant finding from REPEAT is confirmation of the reliability of using a patient's response at 12 weeks as a predictor of treatment success, even in patients with cirrhosis. This means that patients who achieve undetectable virus at 12 weeks can continue treatment with a good likelihood of success. It also means that clinicians can confidently discontinue treatment in patients who do not achieve an early response."


'/>"/>
SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Point of Care Strep Tests Speed Treatment, Lower Costs
2. Rapid HIV Testing Increases Possibility of Treatment
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
9. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
10. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
11. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds "China Orthopedic ... . (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ) ... policy support, China,s orthopedic instrument ... total market size rising from 3.28 billion yuan in ...
(Date:1/15/2014)... 15, 2014  Novation, the leading health care supply chain ... value-added reseller (VAR) national contracts that expand its portfolio ... at lower costs. These include manufacturer product and service ... assistance and ongoing IT consulting support. ...
(Date:1/15/2014)... YORK , January 15, 2014 ... Ltd., the exclusive worldwide distributor of highly sophisticated agro-breeding ... on January 7, 2014, the Company,s board of directors ... Weiner as its new member of the board. ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... Conn., Sept. 16 MedClean Technologies (OTC Bulletin Board: ... technology for the treatment and disposal of medical waste ... today announced it has signed a distribution agreement with ... organization with over 125 years of combined experience in ...
... Quarterly Dividend -- ABBOTT PARK, Ill., Sept. 16 ... ... ... // Results are keyed by longUrl, so we need to grab the first one. for (var r ...
Cached Medicine Technology:MedClean Technologies Signs Distribution Agreement with Trojan Energy Systems 2MedClean Technologies Signs Distribution Agreement with Trojan Energy Systems 3Abbott Declares 347th Consecutive Quarterly Dividend 2Abbott Declares 347th Consecutive Quarterly Dividend 3Abbott Declares 347th Consecutive Quarterly Dividend 4Abbott Declares 347th Consecutive Quarterly Dividend 5Abbott Declares 347th Consecutive Quarterly Dividend 6
(Date:4/24/2014)... the corresponding terminology, and the relevance of palliation ... publications on randomized controlled trials (RCTs). This is ... Institute for Quality and Efficiency in Health Care ... report. , Together with external experts, IQWiG analysed ... lung cancer, malignant melanoma, and pancreatic cancer. For ...
(Date:4/24/2014)... 4/24/14) Dartmouth has been awarded one of 30 ... as a Lead Academic Participating Site in its new ... recipients are a select groups of investigators charged with ... cooperative groups., The NCTN grant system reflects recommendations from ... streamlines operations to achieve four goals:, Faster ...
(Date:4/23/2014)... A pilot study by Massachusetts General Hospital (MGH) investigators ... unusual treatment for a serious medical problem use ... diarrhea caused by the Clostridium difficile ( ... published online in the journal Clinical Infectious Diseases ... fecal material from donors unrelated to patients was as ...
(Date:4/23/2014)... O,Shea, M.D., scientific director at the National Institute of ... named the 2014 recipient of the Ross Prize in ... journal Molecular Medicine . The award will be ... of Sciences in Manhattan, followed by scientific presentations by ... of the National Institutes of Health. , The award, ...
(Date:4/23/2014)... an important enzyme pathway that helps prevent new cells ... condition that has been directly linked to cancer and ... found that near the end of cell division, the ... breaks in DNA are fully repaired before the parent ... This process helps safeguard against some of the most ...
Breaking Medicine News(10 mins):Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 3Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Study identifies enzymes that help fix cancer-causing DNA defects 2
... of terminally ill cancer patients, researchers at Dana-Farber Cancer ... cope with their illness are more likely to receive ... that often entails a lower quality of life in ... more religious patients often prefer aggressive end-of-life (EOL) treatment. ...
... economic crisis contributing to greater workplace stress, providing effective ... than ever. , Unfortunately, the approach most companies take ... unlikely to produce the best outcomes for either their ... Florida State University College of Medicine researcher. , Kathryn ...
... March 17 A federal jury in Miami today ... with a $5.3 million Medicare fraud scheme, Acting Assistant ... and U.S. Attorney R. Alexander Acosta of the Southern ... court in Miami, a jury found David Rothman, M.D., ...
... following event was announced today by the American Red ... Los Angeles Red Cross is hosting a lunch reception ... (EOC), which is ready to be activated during major ... the size of Hurricane Katrina. A video with earthquake ...
... , ... Denver -- As part of its ongoing commitment to encourage ... (AWWA), the authoritative resource on safe water, today announced it will partner ... in Las Vegas., , , , ,Debuted last year by the Southern ...
... but figures decline, report finds , , TUESDAY, March 17 ... abuse in the United States have risen dramatically over ... abuse admissions in 1997 to 5 percent in 2007, ... Alcohol was still the leading cause (40 percent) of ...
Cached Medicine News:Health News:Link between religious coping and aggressive treatment in terminally ill cancer patients 2Health News:Link between religious coping and aggressive treatment in terminally ill cancer patients 3Health News:Researcher wins $2.6 million grant for depression care study 2Health News:Researcher wins $2.6 million grant for depression care study 3Health News:Jury Convicts Two Doctors and Two Medical Assistants in $5.3 Million Medicare Fraud Scam 2Health News:Jury Convicts Two Doctors and Two Medical Assistants in $5.3 Million Medicare Fraud Scam 3Health News:Jury Convicts Two Doctors and Two Medical Assistants in $5.3 Million Medicare Fraud Scam 4Health News:State-of-the-Art Preparedness: L.A. Red Cross Opens Advanced Emergency Operations Center 2Health News:AWWA partners with WaterSmart Innovations conference 2Health News:Admissions for Prescription Painkiller Abuse on Rise 2
Angled for temporal approach. Wire 14 mm rounded blades for patient comfort. Dull finish....
Angled for temporal approach. Open 14 mm rounded blades for patient comfort. Dull finish....
Angled upward 45 degrees for temporal approach. Open 14 mm blades....
Fenestrated 14 mm blades. Self-locking mechanism. Dull finish....
Medicine Products: